The phrase "absence of dose" is correct and usable in written English.
It can be used in contexts related to medicine, pharmacology, or any situation where dosage is relevant, indicating that no dose is present or administered.
Example: "The study showed a significant effect even in the absence of dose, suggesting other factors may be at play."
Alternatives: "lack of dosage" or "no dose present".
One limitation of phytotherapy in traditional medicine is the absence of dose standardization.
It appeared that maintenance of dose density over the first two cycles was the most important factor, with dose intensity and absence of dose delay being equally important.
However, the lack of consistency in the results of various studies and the absence of dose response lead to the conclusion that MMA in not carcinogenic to humans under normal conditions of use [ 104].
It has been found that doxorubicin CMF regimen necessitated further delays subsequently to the first episode in the absence of dose reduction, dose delay, or G-CSF administration (Rivera et al, 2003).
Similar to these investigators, the US EPA separately reviewed oral toxicity data for human sensitivity, experimental animals to human extrapolation, insufficient study length (e.g. 90-day study only), and absence of dose levels without adverse effects (Dourson & Stara, 1983).
To help NTP staff decide on borderline cases, there are 15 additional reference points, or factors to be considered in addressing various aspects, such as "presence or absence of dose relationships" and "statistical significance of the observed tumor increase".
However, this property was not conclusively demonstrated due to the absence of dose-response curves for the (R) and (S) forms of 1-octen-3-ol.
However, both the absence of dose-effect relationship [6] [7] and the trend towards long lasting stable disease rather than tumor shrinkage [4] [5] were observed in the MTA setting.
In the absence of dose-limiting toxicities (DLTs), cohorts were limited to three evaluable patients.
2ME2 inhibits tumor-associated angiogenesis and malignant progression in multiple tumor models in the absence of dose-limiting toxicities.
In the absence of dose-limiting toxicities, only three patients were to be treated at the first two dose levels.
